These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6825388)

  • 1. Imipramine metabolites in blood of patients during therapy and after overdose.
    Gram LF; Bjerre M; Kragh-Sørensen P; Kvinesdal B; Molin J; Pedersen OL; Reisby N
    Clin Pharmacol Ther; 1983 Mar; 33(3):335-42. PubMed ID: 6825388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics.
    Brøsen K; Gram LF; Klysner R; Bech P
    Eur J Clin Pharmacol; 1986; 30(1):43-9. PubMed ID: 3709631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary desipramine hydroxylation index and steady-state plasma concentrations of imipramine and desipramine.
    Spina E; Arena A; Pisani F
    Ther Drug Monit; 1987 Jun; 9(2):129-33. PubMed ID: 3617150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of imipramine, desipramine and their hydroxy metabolites by reversed-phase chromatography with ultraviolet and coulometric detection.
    Foglia JP; Sorisio D; Perel JM
    J Chromatogr; 1991 Dec; 572(1-2):247-58. PubMed ID: 1818058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K; Otton SV; Gram LF
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 37(2):155-60. PubMed ID: 2792169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
    Siris SG; Adan F; Lee A; Cooper TB; Mandeli J; Casey E
    J Clin Psychiatry; 1988 Feb; 49(2):64-5. PubMed ID: 3338977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thin-layer chromatographic determination of imipramine and desipramine in human plasma and urine at single-dose levels.
    Sistovaris N; Dagrosa EE; Keller A
    J Chromatogr; 1983 Oct; 277():273-81. PubMed ID: 6643612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated plasma tricyclic levels with therapeutic doses of imipramine.
    Garvey MJ; Tuason VB; Johnson RA; Valentine RH; Cooper TB
    Am J Psychiatry; 1984 Jul; 141(7):853-6. PubMed ID: 6731633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of imipramine and desipramine.
    Sallee FR; Pollock BG
    Clin Pharmacokinet; 1990 May; 18(5):346-64. PubMed ID: 2185906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic properties of the metabolism of imipramine and desipramine in isolated rat hepatocytes.
    Chiba M; Fujita S; Suzuki T
    Biochem Pharmacol; 1990 Jan; 39(2):367-72. PubMed ID: 2302258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gas chromatographic-mass fragmentographic determation of "steady-state" plasma levels of imipramine and desipramine in chronically treated patients.
    Belvedere G; Burti L; Frigerio A; Pantarotto C
    J Chromatogr; 1975 Sep; 111(2):313-21. PubMed ID: 1159010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels and antidepressive effect of imipramine.
    Gram LF; Reisby N; Ibsen I; Nagy A; Dencker SJ; Bech P; Petersen GO; Christiansen J
    Clin Pharmacol Ther; 1976 Mar; 19(3):318-24. PubMed ID: 770049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration-response relationship in imipramine treatment of diabetic neuropathy symptoms.
    Sindrup SH; Gram LF; Skjold T; Frøland A; Beck-Nielsen H
    Clin Pharmacol Ther; 1990 Apr; 47(4):509-15. PubMed ID: 2328559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The analysis and disposition of imipramine and its active metabolites in man.
    Sutfin TA; DeVane CL; Jusko WJ
    Psychopharmacology (Berl); 1984; 82(4):310-7. PubMed ID: 6427820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of imipramine and desmethylimipramine during therapy.
    Moody JP; Tait AC; Todrick A
    Br J Psychiatry; 1967 Feb; 113(495):183-93. PubMed ID: 6032479
    [No Abstract]   [Full Text] [Related]  

  • 18. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K; Gram LF
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of phenobarbitone on the distribution and elimination of imipramine in rats.
    Lin TH; Sawada Y; Sugiyama Y; Iga T; Hanano M
    J Pharm Pharmacol; 1985 Oct; 37(10):735-8. PubMed ID: 2867146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of imipramine and desipramine in man after different routes of administration.
    Nagy A; Johansson R
    Naunyn Schmiedebergs Arch Pharmacol; 1975; 290(2-3):145-60. PubMed ID: 1102994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.